GeneDx Holdings Corp’s recently made public that its CHIEF FINANCIAL OFFICER Feeley Kevin unloaded Company’s shares for reported $40860.0 on Jul 29 ’25. In the deal valued at $105.31 per share,388 shares were sold. As a result of this transaction, Feeley Kevin now holds 3,757 shares worth roughly $0.4 million.
Then, Stueland Katherine sold 2,154 shares, generating $226,838 in total proceeds. Upon selling the shares at $105.31, the Chief Executive Officer now owns 3,440 shares.
Before that, Feeley Kevin sold 5,278 shares. GeneDx Holdings Corp shares valued at $490,854 were divested by the CHIEF FINANCIAL OFFICER at a price of $93.00 per share. As a result of the transaction, Feeley Kevin now holds 3,392 shares, worth roughly $0.36 million.
Piper Sandler initiated its GeneDx Holdings Corp [WGS] rating to an Overweight in a research note published on July 09, 2025; the price target was $110. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Jefferies also remained covering WGS and has increased its forecast on May 09, 2025 with a “Buy” recommendation from previously “Hold” rating. Wells Fargo started covering the stock on August 28, 2024. It rated WGS as “an Equal weight”.
Price Performance Review of WGS
On Tuesday, GeneDx Holdings Corp [NASDAQ:WGS] saw its stock fall -1.57% to $106.65. Over the last five days, the stock has gained 16.20%. GeneDx Holdings Corp shares have risen nearly 230.70% since the year began. Nevertheless, the stocks have risen 38.76% over the past one year.
How much short interest is there in GeneDx Holdings Corp?
A steep rise in short interest was recorded in GeneDx Holdings Corp stocks on 2025-07-15, dropping by -0.27 million shares to a total of 3.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 3.75 million shares. There was a decline of -7.68%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 10, 2024 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $43 price target.
